Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: OLE & HELIOS-B
Logo

American Heart Association

  138
  0

Final ID:

Discussant: OLE & HELIOS-B

  • Grogan, Martha  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Kittleson, Michelle  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Nair, Ajith  ( Baylor College of Medicine , Houston , Texas , United States )
  • Grodin, Justin  ( UT SOUTHWESTERN , Dallas , Texas , United States )
  • Ambardekar, Amrut  ( , Aurora , Colorado , United States )
    • Author Disclosures:
    Martha Grogan: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Advisor:AztraZeneca:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Research Funding (PI or named investigator):Janssen:Past (completed) ; Research Funding (PI or named investigator):NovoNordisk:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Past (completed) ; Research Funding (PI or named investigator):Eidos:Active (exists now) | Michelle Kittleson: DO NOT have relevant financial relationships | Ajith Nair: DO have relevant financial relationships ; Speaker:Janssen:Active (exists now) ; Consultant:Abbott:Past (completed) ; Advisor:Gossamer Bio:Past (completed) ; Speaker:Impulse Dynamics:Past (completed) | Justin Grodin: DO have relevant financial relationships ; Researcher:Pfizer:Active (exists now) ; Consultant:Tenax Therapeutics:Active (exists now) ; Consultant:Lumanity:Past (completed) ; Consultant:Ultromics:Past (completed) ; Advisor:AstraZeneca:Active (exists now) ; Advisor:Eidos / BridgeBIo:Active (exists now) ; Advisor:Alexion:Past (completed) ; Advisor:Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Eidos / BridgeBio:Past (completed) | Amrut Ambardekar: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis.

Nitsche Christian, Muller Steven, Gama Francisco, Hamdan Ashraf, Kelion Andrew, Schuster Andreas, Glaveckaite Sigita, Porcari Aldostefano, Autherith Maximilian, Hauptmann Laurenz, Halavina Kseniya, Dobner Stephan, Scully Paul, Moon James, Mascherbauer Julia, Biagini Elena, Stortecky Stefan, Maurer Matthew, Treibel Thomas, Rosenblum Hannah, Patel Kush, Longhi Simone, Yilmaz Ali, Merlo Marco, Papathanasiou Maria, Griffin Jan

Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study

Judge Daniel, Masri Ahmad, Obici Laura, Poulsen Steen, Sarswat Nitasha, Shah Keyur, Soman Prem, Cao Xiaofan, Wang Kevin, Pecoraro Maria, Tamby Jean-francois, Gillmore Julian, Katz Leonid, Fox Jonathan, Maurer Mathew, Alexander Kevin, Ambardekar Amrut, Cappelli Francesco, Fontana Marianna, Garcia-pavia Pablo, Grogan Martha, Hanna Mazen

More abstracts from these authors:
The Final Battle: Advanced Heart Failure and AF - HF Top 5 Take Aways

Ambardekar Amrut, Kittleson Michelle

Commentary: Gene Therapy for Cardiac Amyloid

Grogan Martha, Grodin Justin, Ambardekar Amrut

You have to be authorized to contact abstract author. Please, Login
Not Available